PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE Drug Patent Profile

Which patents cover Prilocaine Hydrochloride And Epinephrine Bitartrate, and when can generic versions of Prilocaine Hydrochloride And Epinephrine Bitartrate launch?

Prilocaine Hydrochloride And Epinephrine Bitartrate is a drug marketed by Septodont Inc and is included in one NDA.

The generic ingredient in PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is epinephrine bitartrate; prilocaine hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the epinephrine bitartrate; prilocaine hydrochloride profile page.

Summary for PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	5
DailyMed Link:	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE at DailyMed

Pharmacology for PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

Drug Class	Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Inc	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	078959-001	Aug 30, 2011	AP	RX	No	No

Market Dynamics and Financial Trajectory for Prilocaine Hydrochloride and Epinephrine Bitartrate

Last updated: March 1, 2026

What Are the Key Market Drivers?

The market for Prilocaine Hydrochloride and Epinephrine Bitartrate primarily hinges on:

• Dental anesthesia demand: Prilocaine, combined with epinephrine, is widely used in dental procedures for local anesthesia. The rising global dental procedure volume underpins steady demand.
• Preference over other anesthetics: Prilocaine is favored for its lower risk of methemoglobinemia compared to benzocaine and its comparable efficacy to lidocaine and articaine. This shifts prescribing patterns toward prilocaine-based formulations.
• Growth in dental tourism: Countries with developing dental tourism infrastructure, like Mexico and Thailand, increase the regional market size.
• Regulatory approvals: Approvals by health authorities, such as FDA in the U.S. and EMA in Europe, enhance market penetration and product adoption.

What Are the Market Challenges?

• Competition: Prilocaine faces competition from other local anesthetics like lidocaine and articaine, which have broader global acceptance and established supply chains.
• Patent expiration: Many prilocaine products are off-patent, promoting price competition and generic penetration.
• Pricing pressures: Healthcare systems' cost containment efforts lead to pressure on prices and reimbursement policies.
• Alternative anesthesia methods: Non-pharmacological approaches or newer anesthetic agents could diminish prilocaine demand.

How Is the Market Structured?

Segment	Key Players	Market Share (est.)	Notes
Branded formulations	AstraZeneca (Prilocaine, Embeda), Sandoz, Teva	60%	Dominates due to established brand recognition.
Generics	Multiple regional manufacturers	40%	Price-sensitive segment, increasing in volume.

Regional market distribution:

Region	Market Share	Growth Rate (CAGR 2022–2027)	Notable Factors
North America	35%	4%	High dental procedure volume, mature market.
Europe	30%	3.5%	Stringent regulatory environment, innovation.
Asia-Pacific	25%	6%	Rapid healthcare infrastructure expansion.
Latin America	7%	4.5%	Growing dental tourism and access.
Rest of World	3%	4%	Emerging markets, increasing healthcare access.

What Are the Financial Trends?

Revenue Estimates

• 2022 global sales: Estimated at USD 250 million for prilocaine-based products (excluding specific formulations), reflecting steady growth driven by dental applications.
• Regional revenue share:
  • North America: USD 87.5 million
  • Europe: USD 75 million
  • Asia-Pacific: USD 62.5 million
  • Latin America: USD 11.25 million

Market Growth Projections

• Expected compound annual growth rate (CAGR) from 2022 to 2027: approximately 4–5%. Growth driven mainly by emerging markets and increasing dental procedures globally.
• Price erosion tendency: Generics entering markets lower average selling prices (ASPs), but volume growth partially offsets revenue decline.

Investment and R&D Focus

• Pipeline focus: Companies pursue formulations combining prilocaine with other anesthetics or delivery systems such as controlled-release formulations and intraosseous injections.
• R&D expenditures: Major pharma companies allocate approximately USD 20–30 million annually for new formulations and delivery innovations in local anesthetics.

Who Are the Key Stakeholders?

• Manufacturers: AstraZeneca, Teva, Sandoz, Mylan.
• Regulatory bodies: FDA, EMA, PMDA (Japan).
• Healthcare providers: Dental practitioners, hospitals.
• Distributors: Regional pharmaceutical distributors and hospitals’ pharmacy chains.
• Patients: End users seeking safe, effective anesthesia options.

How Do Patent and Regulatory Landscapes Affect Market Trajectory?

• Many prilocaine formulations are off-patent, enabling broad generic manufacturing.
• Regulatory approvals for new delivery systems or combination products influence market expansion.
• Entry barriers remain moderate, primarily driven by manufacturing costs and regulatory compliance.

How Is Pricing Trending?

• The global average price for a prilocaine cartridge ranges from USD 0.50 to USD 1.00.
• Price competition among generics has driven unit costs down, influencing overall revenue growth.
• Premium formulations with extended release or reduced dose requirements command higher prices but represent a smaller market segment.

Key Takeaways

• The prilocaine and epinephrine market maintains steady growth due to consistent demand in dental procedures.
• Competition from generics and other anesthetics create pricing pressures but are offset by volume growth.
• Emerging markets in Asia-Pacific and Latin America are primary growth regions.
• R&D investment focuses on innovative formulations and delivery systems, which may open new market opportunities.
• Regulatory approval status and patent expiry significantly influence competitive dynamics and product availability.

FAQs

1. How does prilocaine compare to lidocaine in market preference?
   Prilocaine is often preferred for patients with higher methemoglobinemia risk and in procedures requiring lower toxicity profiles, but lidocaine dominates due to broader familiarity and established supply chains.

2. What is the impact of patent expiry for prilocaine products?
   Patent expiration has facilitated generic entry, increasing competition and driving prices down but also reducing profit margins for innovator companies.

3. Which regions are experiencing the fastest growth for prilocaine products?
   The Asia-Pacific region leads with a CAGR of approximately 6%, supported by expanding healthcare infrastructure and dental tourism.

4. Are new formulations or delivery systems emerging in this market?
   Yes, companies pursue controlled-release formulations and intraosseous delivery systems to extend product life cycles and serve niche markets.

5. What are the key regulatory hurdles?
   Regulatory approvals depend on demonstrating safety and efficacy, which can prolong time-to-market for new formulations and limit rapid market expansion.

---

References

[1] IBISWorld. (2022). Dental Anesthesia Market Analysis.
[2] MarketsandMarkets. (2023). Local Anesthetics Market by Type and Application.
[3] U.S. Food and Drug Administration. (2022). Regulatory Approval Data.
[4] IQVIA. (2022). Global Pharmaceutical Market Report.
[5] European Medicines Agency. (2022). Product approvals and market insights.